Register for our free email digests:
Latest From Medtronic PLC
Approvals of neurostimulation and cardiology devices dominated the list of non-US medtech approvals in June. According to Medtech Insight's Approvals Tracker, there were 36 medtech approvals outside the US last total that month, including 28 CE marks in Europe, plus approvals from China, Canada, Australia/New Zealand and Brazil.
US FDA Device-approval volumes were strong during the first half of 2017 for all review pathways. Medtronic and Siemens have so far captured the most 510(k) clearances, with Cook close behind. That and more from Medtech Insight's Approvals Tracker.
Despite a major a computer crash, Medtronic is confident it will meet its revenue growth projections for the first quarter. The company also says there is currently no indication the crash was the result of an outside agent such as the recent WannaCry and Petya worms.
The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.